#Retroperitoneal Liposarcoma Treatment Market
Explore tagged Tumblr posts
Visit Tumblr Blog
Explore Tumblr blogs with no restrictions, modern design and the best experience.
Last Seen Tumblr Blogs
Fun Fact
Tumblr has 16.74 million mobile monthly users in the US.
Text
Current Knowledge on the Diagnosis and Management of Retroperitoneal Liposarcoma Treatment
RLS (retroperitoneal liposarcoma) is a rare, physiologically heterogeneous cancer that develops in the retroperitoneum, the lining of the abdominal cavity that surrounds the abdominal organs. Retroperitoneal Liposarcoma Treatment grow constantly and are often not identified until they are very large, hence their prognosis is poor when compared to other retroperitoneal sarcoma subtypes.
Although the cause of these tumours is uncertain, genetic mutation is thought to be one of the elements that contribute to their growth. Men and women are equally affected by this condition, with men having a slight advantage. This tumour has no distinguishing signs and is usually discovered when it has progressed to an advanced stage.
Read more @ https://digitalgrowinfo.blogspot.com/2022/02/retroperitoneal-liposarcoma-treatment.html
0 notes
Text
Retroperitoneal Liposarcoma Treatment Market Size Share Trends Forecast 2026
Retroperitoneal Liposarcoma Treatment Market – Drivers
The global Retroperitoneal Liposarcoma Treatment Market is expected to exhibit a moderate growth rate, owing to low incidence of this disease across the globe. According to the World Health Organization (WHO) 2016, liposarcoma is the most common type of sarcomas (cancer of soft tissue) and is classified as a rare disease, which accounts for around 17-20% of all the cases (2.5 per Mn population) of sarcoma. Furthermore, rising incidence of genetic disorders is one of the major factors responsible for the global retroperitoneal liposarcoma treatment market growth. According to a report published by the Genetics Education Center, University of Kansas Medical Center, around 15% of all the cancers have an inherited susceptibility and around 12% of the hospital admissions in the U.S. accounted for the treatment of genetic causes in 2013. Various other factors contributing to market growth include changing lifestyle and growing awareness among populace regarding availability of treatment for liposarcoma through initiatives undertaken by various organizations. For instance, Liposarcoma Genome Project initiative by Massachusetts General Hospital Cancer Center conducted research to understand the differences between well-differentiated and de-differentiated liposarcoma, to support the development of treatment for the rare disease. However, high costs associated with the treatment procedures and low accessibility of the treatment due to rareness of the disease are expected to be factors hindering the market growth.
Retroperitoneal liposarcoma (RLS) is a rare, biologically heterogeneous cancer, which occurs in retroperitoneum, lining of the abdominal space that covers the abdominal organs. Retroperitoneal liposarcoma grow continuously and may not get diagnosed until they are very large thus, its prognosis is poor compared to the other subtypes of retroperitoneal sarcomas.
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/1861
The reason for the development of these tumors are still unknown, however, genetic mutation is considered to be one of the factors leading to the generation of these tumors. Incidence of this disease is equal in men and women, with a slight predominance of men. This tumor has no characteristic symptoms and are usually diagnosed during the advanced stage.
Furthermore, the effectiveness of radiotherapy or chemotherapy for the treatment of this tumor is not properly defined, as they are massive in size and might involve adjacent visceral organs and critical structures. However, affected population who received adjuvant chemotherapy showed survival benefits and improvement, as compared to patients who underwent surgery alone. In the case of surgeries, sometimes, preoperative radiation is given to shrink the tumor. This allows smaller doses of radiation to a smaller field and make the surgery technically more feasible. The European Organisation for Research and Treatment of Cancer (EORTC) is currently conducting a randomized trial comparing 50.4 Gy (Gray-unit to measure radiation therapy) of pre-operative radiation therapy with short-course radiotherapy, followed by surgery to direct surgery alone. Thus, continuous researches that are being conducted for the development of treatment for this disease is expected to create lucrative opportunities in the retroperitoneal liposarcoma treatment market during the forecast period.
Retroperitoneal Liposarcoma Treatment Market - Regional Analysis
On the basis of region, the global retroperitoneal liposarcoma treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America holds the maximum share for retroperitoneal liposarcoma treatment, owing to increasing research and development of novel therapies and potential drugs for dedifferentiated liposarcoma. For instance, the Sarcoma Foundation of America (SFA) aids sarcoma patients by providing funding for research to private researchers and conducts education campaigns for patients suffering from various types of sarcomas.
Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/retroperitoneal-liposarcoma-treatment-market-1861
Furthermore, Asia pacific also generates the significant value in retroperitoneal liposarcoma treatment market, owing to the presence of significant population suffering from the disease in this region. For instance, according to the Journal of Blood & Lymph 2013, in India around 35% of the patients suffering from sarcoma died due to dedifferentiated liposarcoma.
Retroperitoneal liposarcoma Treatment Market – Competitor Landscape
Increasing regulatory approvals by the U.S. FDA for various products manufactured by large companies is expected to boost the overall growth of the retroperitoneal liposarcoma treatment market. For instance, in 2015, the U.S. FDA granted priority review for the New Drug Application (NDA) for YONDELIS (trabectedin), manufactured by Janssen Research & Development, LLC to treat patients with advanced soft tissue sarcoma (STS), which includes liposarcoma and leiomyosarcoma subtypes in 77 countries, within North America, Europe, South America, and Asia. Furthermore, in 2016, Eisai Co., Ltd. received the approval in Japan for its in-house developed anticancer agent Halaven (eribulin mesylate) for the treatment of patients suffering from soft tissue sarcoma.
Market players operating in the global retroperitoneal liposarcoma treatment market include Eli Lilly and Company, Baxter International, Bristol Laboratories Ltd., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Actavis plc, Fresenius Kabi Ltd., Accord Healthcare Inc., Taro Pharmaceuticals Inc., Sandoz, Bedford Laboratories, and Zydus Cadila.
Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/1861
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
mailto:[email protected]
U.S. Office:
Name: Mr. Shah
Coherent Market Insights 1001 4th Ave,
# 3200 Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
0 notes
Text
Retroperitoneal Liposarcoma Treatment Market Insight Strategies Volume Outlook
Retroperitoneal liposarcoma (RLS) is a rare, biologically heterogeneous cancer, which occurs in retroperitoneum, lining of the abdominal space that covers the abdominal organs. Retroperitoneal liposarcoma grow continuously and may not get diagnosed until they are very large thus, its prognosis is poor compared to the other subtypes of retroperitoneal sarcomas.
The reason for the development of these tumors are still unknown, however, genetic mutation is considered to be one of the factors leading to the generation of these tumors. Incidence of this disease is equal in men and women, with a slight predominance of men. This tumor has no characteristic symptoms and are usually diagnosed during the advanced stage.
Request A Sample Copy: http://bit.ly/32Suolt
Furthermore, the effectiveness of radiotherapy or chemotherapy for the treatment of this tumor is not properly defined, as they are massive in size and might involve adjacent visceral organs and critical structures. However, affected population who received adjuvant chemotherapy showed survival benefits and improvement, as compared to patients who underwent surgery alone. In the case of surgeries, sometimes, preoperative radiation is given to shrink the tumor.
This allows smaller doses of radiation to a smaller field and make the surgery technically more feasible. The European Organisation for Research and Treatment of Cancer (EORTC) is currently conducting a randomized trial comparing 50.4 Gy (Gray-unit to measure radiation therapy) of pre-operative radiation therapy with short-course radiotherapy, followed by surgery to direct surgery alone. Thus, continuous researches that are being conducted for the development of treatment for this disease is expected to create lucrative opportunities in the retroperitoneal liposarcoma treatment market during the forecast period.
Retroperitoneal Liposarcoma Treatment Market – Drivers
The global retroperitoneal liposarcoma treatment market is expected to exhibit a moderate growth rate, owing to low incidence of this disease across the globe. According to the World Health Organization (WHO) 2016, liposarcoma is the most common type of sarcomas (cancer of soft tissue) and is classified as a rare disease, which accounts for around 17-20% of all the cases (2.5 per Mn population) of sarcoma. Furthermore, rising incidence of genetic disorders is one of the major factors responsible for the global retroperitoneal liposarcoma treatment market growth. According to a report published by the Genetics Education Center, University of Kansas Medical Center, around 15% of all the cancers have an inherited susceptibility and around 12% of the hospital admissions in the U.S.
accounted for the treatment of genetic causes in 2013. Various other factors contributing to market growth include changing lifestyle and growing awareness among populace regarding availability of treatment for liposarcoma through initiatives undertaken by various organizations. For instance, Liposarcoma Genome Project initiative by Massachusetts General Hospital Cancer Center conducted research to understand the differences between well-differentiated and de-differentiated liposarcoma, to support the development of treatment for the rare disease.
Retroperitoneal Liposarcoma Treatment Market - Regional Analysis
On the basis of region, the global retroperitoneal liposarcoma treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America holds the maximum share for retroperitoneal liposarcoma treatment, owing to increasing research and development of novel therapies and potential drugs for dedifferentiated liposarcoma.
For instance, the Sarcoma Foundation of America (SFA) aids sarcoma patients by providing funding for research to private researchers and conducts education campaigns for patients suffering from various types of sarcomas. Furthermore, Asia pacific also generates the significant value in retroperitoneal liposarcoma treatment market, owing to the presence of significant population suffering from the disease in this region. For instance, according to the Journal of Blood & Lymph 2013, in India around 35% of the patients suffering from sarcoma died due to dedifferentiated liposarcoma.
Click To Read More On: Retroperitoneal Liposarcoma Treatment Market
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:[email protected]
0 notes
Text
Pediatric Liposarcoma Treatment Market Predicted to Witness Surge in The Near Future
The Pediatric liposarcoma is one of the rare nonrhabdomyosarcoma soft tissue sarcomas that occurs in childhood. It accounts for less than 6% of overall soft tissue sarcomas found in childhood. Roughly, less than 200 cases of pediatric liposarcoma have been reported in the last decade. Liposarcomas are tumors derived from primitive messenchymal cells which undergo adipose differentiations. Three common locations where liposarcomas are found are the retroperitoneal region, shoulder area, and lower extremities. These occur primarily in the lower extremities, which includes poploiteal fossa and medial thigh. In some cases, tumors can originate from the neck, facial areas, and subcutis of shoulder. Research findings suggest children tend to have higher incidence of lower extremity tumors. As the research date on pediatric liposarcoma are limited, on that basis it is imprecise whether outcomes of pediatric patients and the clinical features are similar in comparison with adults. As the management of the liposarcoma in this age group is largely based on research findings of the adult data. Outcome of pediatric liposarcomas is linked with a number of factors such as stage, grade, and prognostic factors.
Request a Sample of Pediatric Liposarcoma Treatment Market: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=37832
The global pediatric liposarcoma treatment market is projected to grow at a rapid pace in the next few years, as this condition is are and represents nearly 2 to 6 % of all childhood soft tissue sarcomas and the data is very limited for diagnosis and treatment of the disease. Significant investments by top pharma and biotech companies in cancer research is a major factor driving the market. In 2016, an anticipated 1,785,210 new cases of cancer will be diagnosed in the U.S. alone and nearly 596,698 will succumb to the disease. Increase in cancer awareness among people, benefits of early diagnosis and treatment, and acceptance of new advanced techniques are the other factors likely to propel the global pediatric liposarcoma treatment market. Additionally, launch of pipeline products of top pharma companies in the near future, favorable reimbursement policies in developed countries such as the U.S., the U.K. France, and Germany are expected to augment the global market. However, rise in cost of treatment and side effects associated with chemotherapy are the key factors anticipated to restrain the global pediatric liposarcoma treatment market.
Enquiry before Buying Pediatric Liposarcoma Treatment Market Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=37832
The global pediatric liposarcoma treatment market can be segmented based on subtype, age group, treatment, and region. In terms of subtype, the global market can be divided into pleomorphic tumors, round-cell tumors, myxoid tumors, and well-differentiated tumors. Based on age group, the global pediatric liposarcoma treatment market can be bifurcated into between 1 and 5 years and 6 and 10 years. Based on treatment, the global market can be categorized into complete surgical resection, adjuvant radiation therapy, and others. In terms of region, the global pediatric liposarcoma treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is projected to grow rapidly in the next few years. This is attributed to well-developed health care system, favorable reimbursement scenario, and acceptance of new advanced techniques. Europe and Asia Pacific are the other major markets for pediatric liposarcoma treatment. Presence of key players and rise in investments in research and development by top players, and collaboration of key players with research institutes are driving the global pediatric liposarcoma treatment market.
Pre-book Pediatric Liposarcoma Treatment Market Report- https://www.transparencymarketresearch.com/checkout.php?rep_id=37832<ype=S
Top players in the global pediatric liposarcoma treatment market are Johnson & Johnson, Roche Ag, Pfizer, Eisai, Inc., and Affymetrix, Inc., among others.
More Trending Reports by Transparency Market Research:
https://www.prnewswire.co.uk/news-releases/continuous-r-amp-d-to-expand-therapeutic-use-of-platelet-rich-plasma-prp-in-regenerative-therapies-offer-profitable-opportunities-to-platelet-rich-plasma-market-players-global-market-valuation-to-reach-us-811-34-mn-by-2030-tmr-study-825481498.html
https://www.prnewswire.com/news-releases/increase-in-demand-for-new-therapies-for-effective-management-to-drive-global-menopausal-hot-flashes-treatment-market-says-tmr-301378552.html
https://www.prnewswire.com/news-releases/plant-based-vaccines-market-is-expected-to-reach-us-2-34-billion-by-2031-end-emergence-of-numerous-infectious-diseases-to-fuel-growth-of-the-market-says-tmr-301385503.html
About Us
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
US Office Contact
90 State Street, Suite 700 Albany, NY 12207 Tel: +1-518-618-1030 USA - Canada Toll Free: 866-552-3453 Website: https://www.transparencymarketresearch.com
0 notes
Text
0 notes
Text
Dedifferentiated Liposarcoma Treatment Market 2018 Growth by Opportunities, Application, Driver, Current Trends and Forecast by 2026
Liposarcoma refers to one of the most commonly diagnosed type of soft tissue sarcomas. It is a type of cancer that originates from the fat cells in deep tissues. On the other hand, dedifferentiated Liposarcoma is the least common subtypes among all types of sarcomas and arises from a well-differentiated sarcoma. The tumors of dedifferentiated Liposarcoma are typically present in the retroperitoneal/abdominal cavity followed by the limbs. The reason for development of these tumors are still unknown, however, genetic mutations is considered to be one of the factors in generation of these tumors. The most commonly employed treatment for dedifferentiated sarcoma includes complete excision and removal of the tumor by various therapies such as liposuction and targeted immunotherapy.
Dedifferentiated Liposarcoma does not have any gender predilection, however, is commonly found in patients over the age of 50 years. The global dedifferentiated Liposarcoma treatment market is expected to exhibit a moderate growth rate, which attributes to low incidence of the disease across the globe. According to the World Health Organization 2016, the incidence rate of well-differentiated Liposarcoma accounts for 2.5 per million, wherein de-differentiated Liposarcoma accounts for 18% of the total incidence of Liposarcoma across the globe.
Regional Insights
On the basis of region, the global dedifferentiated Liposarcoma treatment market by Coherent Market Insights is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America holds the dominant position in the global dedifferentiated Liposarcoma treatment market, owing to increasing research and development of novel therapies and potential drugs for dedifferentiated Liposarcoma. For instance, the Sarcoma Foundation of America (SFA) aids sarcoma patients by providing funding for research to private researchers and conducts education campaigns for patients suffering from various types of sarcomas.
Request For Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/1532
Competitive Analysis
Key players operating in the global dedifferentiated Liposarcoma treatment market include Johnson & Johnson Services, Inc., Eli Lily & Company, Novartis AG, Pfizer, Inc. and Sanofi SA. Major players are focusing on innovation and development, to maintain their position in the market and enhance its share. For instance, in July 2017, Karyopharm Therapeutics, Inc. cleared Phase II clinical trial for Selinexor, an orally administered inhibitor of CRM1, to treat patients with unresectable dedifferentiated liposarcoma.
#Dedifferentiated Liposarcoma Treatment Market#Dedifferentiated Liposarcoma Treatment#Dedifferentiated Liposarcoma Treatment Market 2026#Pharmaceutical
0 notes
Text
Dedifferentiated Liposarcoma Treatment Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026
Liposarcoma refers to one of the most commonly diagnosed type of soft tissue sarcomas. It is a type of cancer that originates from the fat cells in deep tissues. On the other hand, dedifferentiated Liposarcoma is the least common subtypes among all types of sarcomas and arises from a well-differentiated sarcoma. The tumors of dedifferentiated Liposarcoma are typically present in the retroperitoneal/abdominal cavity followed by the limbs. The reason for development of these tumors are still unknown, however, genetic mutations is considered to be one of the factors in generation of these tumors. The most commonly employed treatment for dedifferentiated sarcoma includes complete excision and removal of the tumor by various therapies such as liposuction and targeted immunotherapy. Dedifferentiated Liposarcoma does not have any gender predilection, however, is commonly found in patients over the age of 50 years. The global dedifferentiated Liposarcoma treatment market is expected to exhibit a moderate growth rate, which attributes to low incidence of the disease across the globe. According to the World Health Organization 2016, the incidence rate of well-differentiated Liposarcoma accounts for 2.5 per million, wherein de-differentiated Liposarcoma accounts for 18% of the total incidence of Liposarcoma across the globe.
Regional Insights
On the basis of region, the global dedifferentiated Liposarcoma treatment market by Coherent Market Insights is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America holds the dominant position in the global dedifferentiated Liposarcoma treatment market, owing to increasing research and development of novel therapies and potential drugs for dedifferentiated Liposarcoma. For instance, the Sarcoma Foundation of America (SFA) aids sarcoma patients by providing funding for research to private researchers and conducts education campaigns for patients suffering from various types of sarcomas.
Furthermore, Asia Pacific market is expected to gain significant traction in the near future, owing to increasing research and development of new drugs and immunotherapies, to combat the disease as well as presence of significant population suffering from the disease in this region. For instance, according to the Journal of Blood & Lymph 2013, in India up to 35% of patients suffering with Sarcoma died due to dedifferentiated Liposarcoma, wherein the total number of deaths as a result of sarcoma was reported to be 328 patients in 2012.
Competitive Analysis
Key players operating in the global dedifferentiated Liposarcoma treatment market include Johnson & Johnson Services, Inc., Eli Lily & Company, Novartis AG, Pfizer, Inc. and Sanofi SA. Major players are focusing on innovation and development, to maintain their position in the market and enhance its share. For instance, in July 2017, Karyopharm Therapeutics, Inc. cleared Phase II clinical trial for Selinexor, an orally administered inhibitor of CRM1, to treat patients with unresectable dedifferentiated liposarcoma.
Market Taxonomy:
The chemotherapy segment is expected to be dominant, owing to widespread availability of drugs across the world. According to the British Medical Journal, the European Medical Agency approved the use of 48 cancer drugs for 68 indications in Europe. Moreover, patent expiry is leading to entrance of large number of generic players in the market, which also propels growth of chemotherapy segment. However, immunotherapy is expected to gain marginal traction in the forecast period, owing to extensive research and development associated with the implementation of targeted cell therapy and other immunotherapies that have lower side effects than the chemotherapy. According to Memorial Sloan Kettering Cancer Center 2015, checkpoint inhibitor based immunotherapy is being effectively tested against dedifferentiated Liposarcoma and has potential benefits in treating the disorder.
Ask For Discount Before Purchasing This Business Report @ https://www.coherentmarketinsights.com/insight/request-discount/1532
On the basis of treatment type, the global dedifferentiated Liposarcoma treatment market is segmented into:
Chemotherapy
Immunotherapy
Radiation Therapy
On the basis of end user, the global dedifferentiated Liposarcoma treatment market is segmented into:
Hospitals
Multispecialty Clinics
Cancer Treatment & Rehabilitation Centers
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]
0 notes
Text
Retroperitoneal Liposarcoma Treatment Market Share, Outlook 2026
Retroperitoneal liposarcoma (RLS) is a rare, biologically heterogeneous cancer, which occurs in retroperitoneum, lining of the abdominal space that covers the abdominal organs. Retroperitoneal liposarcoma grow continuously and may not get diagnosed until they are very large thus, its prognosis is poor compared to the other subtypes of retroperitoneal sarcomas. The reason for the development of these tumors are still unknown, however, genetic mutation is considered to be one of the factors leading to the generation of these tumors. Incidence of this disease is equal in men and women, with a slight predominance of men. This tumor has no characteristic symptoms and are usually diagnosed during the advanced stage.
Click To Continue Reading on Retroperitoneal Liposarcoma Treatment Market
Furthermore, the effectiveness of radiotherapy or chemotherapy for the treatment of this tumor is not properly defined, as they are massive in size and might involve adjacent visceral organs and critical structures. However, affected population who received adjuvant chemotherapy showed survival benefits and improvement, as compared to patients who underwent surgery alone. In the case of surgeries, sometimes, preoperative radiation is given to shrink the tumor. This allows smaller doses of radiation to a smaller field and make the surgery technically more feasible.
0 notes
Text
Soft Tissue Sarcoma Market Analysis, Market Growth and Industry Analysis
DelveInsight’s launched a new report on “Soft Tissue Sarcoma Market Insights, Epidemiology, and Market Forecast-2030”. The report deliver an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Soft Tissue Sarcoma (STS) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The Soft Tissue Sarcoma market report provides analysis regarding current treatment practices, emerging drugs like AL3818, Fibromun, AL3818, Ripretinib, market share of the individual therapies, historical, current and forecasted Soft Tissue Sarcoma market Size from 2017 to 2030 segmented by seven major markets.
Soft Tissue Sarcoma
Soft Tissue Sarcoma Overview
Soft-tissue sarcoma are rare neoplasms that can develop in supporting or connective tissue, such as the muscle, nerves, tendons, blood vessels, and fatty and fibrous tissues. They commonly affect the arms, legs, and trunk. They also appear in the stomach and intestines (GIST) as well as behind the abdomen (retroperitoneal sarcomas) and the female reproductive system (gynecological sarcomas). STSs may be classified according to the involved cell-type, the specific nature of the malignancy, and the disease’s clinical course.
According to the World Health Organization (WHO), there are more than 50 histologic subtypes of STSs. The signs and symptoms of STSs vary greatly from patients to patients based on the type of STS. However, it is not associated with any noticeable symptoms early in the course of the disease, but the affected individuals may notice slow-growing, painless mass in the affected area.
Soft Tissue Sarcoma Treatment
This chapter covers the details of conventional and current medical therapies available in the Soft tissue sarcoma market for the treatment of the condition. It also provides the country-wise Soft Tissue Sarcoma treatment guidelines and algorithm across the United States, Europe and Japan.
DelveInsight’s Soft tissue sarcoma market report gives a thorough understanding of the disease by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides Soft tissue sarcoma treatment algorithms and treatment guidelines in the US, Europe, and Japan.
Soft Tissue Sarcoma Epidemiology
Soft Tissue Sarcoma has various subtypes. It was observed that in the United States and European countries, liposarcoma and leiomyosarcoma were the most incident subtypes of STS, which contributed to the majority of the cases. Whereas in Japan, subtypes, fibroblastic sarcomas and liposarcoma were more common.
According to DelveInsight’s, the total Soft Tissue Sarcoma incident population in seven major markets was 40,155 in 2017. These cases are expected to increase with a significant CAGR during the study period (2017–2030).
Among all the seven major markets, the United States accounts for the highest number of Soft Tissue Sarcoma cases. In 2017, there were 12,390 incident cases of STS—which did not include GIST cases—in the United States. The total incident cases of GIST which were observed in the United States in 2017 accounted for 5,090. This lead to the total Soft Tissue Sarcoma incident population to 17,480 in 2017.
Soft Tissue Sarcoma Drug Chapters
Drug chapter segment of the Soft Tissue Sarcoma report encloses the detailed analysis of Soft Tissue Sarcoma marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Soft Tissue Sarcoma clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
The report provides the details of the emerging therapies under the late and mid-stage of development for Soft Tissue Sarcoma treatment and marketed product available for Soft Tissue Sarcoma treatment.
STS primarily encountered in adults but can affect patients of any age. There are many histologic subtypes, and the malignancy can be low or high grade. Soft tissue sarcoma treatments may include surgery, chemotherapy, radiation therapy, or a combination of these therapies.
The emerging therapies are classified into four categories based on their line of therapy. The upcoming first-line therapies that are going to be launched in the forecasted period includes, AL3818 (anlotinib) and Fibromun. The second-line emerging therapies include Vigil in combination with irinotecan and temozolomide, AL3818, GSK 3377794, Ripretinib (DCC-2618), Tazemetostat, Abemaciclib, Pembrolizumab, Crizotinib, ABI-009, and SRA737. The third-line emerging therapies include Avapritinib, Cabozantinib, and Selinexor. The fourth-line emerging therapies include Avapritinib, TAS-116, Crenolanib, and Ripretinib.
Soft Tissue Sarcoma Market Outlook
The Soft Tissue Sarcoma market size is expected to increase at a significant CAGR during the study period (2017–2030). Among all the seven major markets, the United States accounts for the highest Soft Tissue Sarcoma market size. Among EU5, Germany had the highest Soft Tissue Sarcoma market size in 2017 USD 22.06 million, followed by Italy. The market size of STS (excluding GIST) in Japan was found to be least in 2017.
The key companies involved for Soft Tissue Sarcoma market treatment are Amgen, BioPharma, AstraZeneca and many others.
Soft Tissue Sarcoma Drugs Uptake
The current Soft Tissue Sarcoma market size is mainly attributed to Votrient, Yondelis, Halaven, and various anthracycline and non-anthracycline regimens. The market size of GIST in the United States was found to be USD 119.7 million in 2017 and expected to increase during the forecast period (2020–2030) due to potential therapies Vitrakvi, Rozlytrek, Avapritinib, Ripretinib and others.
View full report @https://www.delveinsight.com/report-store/soft-tissue-sarcoma-market
Frequently asked questions:
At what CAGR, Soft Tissue Sarcoma market is expected to grow for the study period 2017-30?
The Soft Tissue Sarcoma market is expected to increase at a CAGR of 6.47% during forecast period (2017-2030).
Which geography accounted for the largest Soft Tissue Sarcoma market size?
United States accounted for the largest Soft Tissue Sarcoma market size.
What is forecasted soft tissue sarcoma market size in 2030?
DelveInsight estimates an increase in STS Market Size during the study period, 2017–2030
What are the present Soft Tissue Sarcoma market drivers?
Competitive Landscape, Precision Medicine Approach & Novel Therapies for Subtype of STS.
What are the Soft Tissue Sarcoma market barriers?
High Cost of Treatment, Stringent Government Regulations & High Failure Rate in the Clinical Trials.
How many companies are developing drugs for soft tissue sarcoma?
Currently more than 8 companies are developing drugs for soft tissue sarcoma.
Which are the leading companies in soft tissue sarcoma market?
Key Companies - Bayer, Gradalis, Karyopharm, Novartis, Eli Lilly, GlaxoSmithKline, Merck Sharp& Dohme Corp. and several others.
How is epidemiology segmented for soft tissue sarcoma?
Total Incident Cases of STS in the 7MM, Gender-Specific Incidence of STS in the 7MM, Gender-Specific Incidence of STS in the 7MM, Incidence of STS by Extremities (%) in the 7MM, Stage-Specific Incidence of STS in the 7MM and Age-Specific Incidence of STS in the 7MM.
Request for free sample pages: https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-market
#soft tissue sarcoma#soft tissue sarcoma market#soft tissue sarcoma market share#soft tissue sarcoma market size#Soft Tissue Sarcoma market size and share#soft tissue sarcoma market trends#soft tissue sarcoma key companies#soft tissue sarcoma epidemiology
0 notes
Text
Pediatric Liposarcoma Treatment Market Research Report by Key Players Analysis 2025
The Pediatric liposarcoma is one of the rare nonrhabdomyosarcoma soft tissue sarcomas that occurs in childhood. It accounts for less than 6% of overall soft tissue sarcomas found in childhood. Roughly, less than 200 cases of pediatric liposarcoma have been reported in the last decade. Liposarcomas are tumors derived from primitive messenchymal cells which undergo adipose differentiations. Three common locations where liposarcomas are found are the retroperitoneal region, shoulder area, and lower extremities. These occur primarily in the lower extremities, which includes poploiteal fossa and medial thigh. In some cases, tumors can originate from the neck, facial areas, and subcutis of shoulder. Research findings suggest children tend to have higher incidence of lower extremity tumors. As the research date on pediatric liposarcoma are limited, on that basis it is imprecise whether outcomes of pediatric patients and the clinical features are similar in comparison with adults. As the management of the liposarcoma in this age group is largely based on research findings of the adult data. Outcome of pediatric liposarcomas is linked with a number of factors such as stage, grade, and prognostic factors.
Browse Premium Industry Research Report with Analysis: https://www.transparencymarketresearch.com/pediatric-liposarcoma-treatment-market.html
The global pediatric liposarcoma treatment market is projected to grow at a rapid pace in the next few years, as this condition is are and represents nearly 2 to 6 % of all childhood soft tissue sarcomas and the data is very limited for diagnosis and treatment of the disease. Significant investments by top pharma and biotech companies in cancer research is a major factor driving the market. In 2016, an anticipated 1,785,210 new cases of cancer will be diagnosed in the U.S. alone and nearly 596,698 will succumb to the disease. Increase in cancer awareness among people, benefits of early diagnosis and treatment, and acceptance of new advanced techniques are the other factors likely to propel the global pediatric liposarcoma treatment market. Additionally, launch of pipeline products of top pharma companies in the near future, favorable reimbursement policies in developed countries such as the U.S., the U.K. France, and Germany are expected to augment the global market. However, rise in cost of treatment and side effects associated with chemotherapy are the key factors anticipated to restrain the global pediatric liposarcoma treatment market.
Request for Sample Copy of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=37832
The global pediatric liposarcoma treatment market can be segmented based on subtype, age group, treatment, and region. In terms of subtype, the global market can be divided into pleomorphic tumors, round-cell tumors, myxoid tumors, and well-differentiated tumors. Based on age group, the global pediatric liposarcoma treatment market can be bifurcated into between 1 and 5 years and 6 and 10 years. Based on treatment, the global market can be categorized into complete surgical resection, adjuvant radiation therapy, and others. In terms of region, the global pediatric liposarcoma treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is projected to grow rapidly in the next few years. This is attributed to well-developed health care system, favorable reimbursement scenario, and acceptance of new advanced techniques. Europe and Asia Pacific are the other major markets for pediatric liposarcoma treatment. Presence of key players and rise in investments in research and development by top players, and collaboration of key players with research institutes are driving the global pediatric liposarcoma treatment market.
Top players in the global pediatric liposarcoma treatment market are Johnson & Johnson, Roche Ag, Pfizer, Eisai, Inc., and Affymetrix, Inc., among others.
Request For Discount On This Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=37832
About Us
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
Contact US:
Transparency Market Research, 90 State Street, Suite 700, Albany NY – 12207 United States Tel: +1-518-618-1030 Email: [email protected] Website: https://www.transparencymarketresearch.com
0 notes
Text
Soft Tissue Sarcoma Market Size and Share | Soft Tissue Sarcoma | DelveInsight
DelveInsight’s ‘Soft Tissue Sarcoma Market Insights, Epidemiology, and Market Forecast-2030’ report deliver an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Soft Tissue Sarcoma (STS) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The Soft Tissue Sarcoma market report provides analysis regarding current treatment practices, emerging drugs like AL3818, Fibromun, AL3818, Ripretinib, market share of the individual therapies, historical, current and forecasted Soft Tissue Sarcoma market Size from 2017 to 2030 segmented by seven major markets.
The Report also covers current Soft Tissue Sarcoma treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.
Geography Covered
· The United States
· EU5 (Germany, France, Italy, Spain, and the United Kingdom)
· Japan
Soft Tissue Sarcoma - Disease Understanding and Treatment Algorithm
Soft Tissue Sarcoma Overview
Soft-tissue sarcoma are rare neoplasms that can develop in supporting or connective tissue, such as the muscle, nerves, tendons, blood vessels, and fatty and fibrous tissues. They commonly affect the arms, legs, and trunk. They also appear in the stomach and intestines (GIST) as well as behind the abdomen (retroperitoneal sarcomas) and the female reproductive system (gynecological sarcomas). STSs may be classified according to the involved cell-type, the specific nature of the malignancy, and the disease’s clinical course.
According to the World Health Organization (WHO), there are more than 50 histologic subtypes of STSs. The signs and symptoms of STSs vary greatly from patients to patients based on the type of STS. However, it is not associated with any noticeable symptoms early in the course of the disease, but the affected individuals may notice slow-growing, painless mass in the affected area.
Soft Tissue Sarcoma Treatment
This chapter covers the details of conventional and current medical therapies available in the Soft tissue sarcoma market for the treatment of the condition. It also provides the country-wise Soft Tissue Sarcoma treatment guidelines and algorithm across the United States, Europe and Japan.
DelveInsight’s Soft tissue sarcoma market report gives a thorough understanding of the disease by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides Soft tissue sarcoma treatment algorithms and treatment guidelines in the US, Europe, and Japan.
Soft Tissue Sarcoma Epidemiology
The Soft Tissue Sarcoma epidemiology chapters provide insights about historical and current Soft Tissue Sarcoma patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. Soft tissue sarcoma epidemiology is segmented by gender-specific incidence, type-specific incidence, age-specific, stage-specific, and extremities. The report includes thorough analysis of all segmentations.
Soft Tissue Sarcoma has various subtypes. It was observed that in the United States and European countries, liposarcoma and leiomyosarcoma were the most incident subtypes of STS, which contributed to the majority of the cases. Whereas in Japan, subtypes, fibroblastic sarcomas and liposarcoma were more common.
According to DelveInsight’s, the total Soft Tissue Sarcoma incident population in seven major markets was 40,155 in 2017. These cases are expected to increase with a significant CAGR during the study period (2017–2030).
Among all the seven major markets, the United States accounts for the highest number of Soft Tissue Sarcoma cases. In 2017, there were 12,390 incident cases of STS—which did not include GIST cases—in the United States. The total incident cases of GIST which were observed in the United States in 2017 accounted for 5,090. This lead to the total Soft Tissue Sarcoma incident population to 17,480 in 2017.
Soft Tissue Sarcoma Drug Chapters
Drug chapter segment of the Soft Tissue Sarcoma report encloses the detailed analysis of Soft Tissue Sarcoma marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Soft Tissue Sarcoma clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
The report provides the details of the emerging therapies under the late and mid-stage of development for Soft Tissue Sarcoma treatment and marketed product available for Soft Tissue Sarcoma treatment.
STS primarily encountered in adults but can affect patients of any age. There are many histologic subtypes, and the malignancy can be low or high grade. Soft tissue sarcoma treatments may include surgery, chemotherapy, radiation therapy, or a combination of these therapies.
The emerging therapies are classified into four categories based on their line of therapy. The upcoming first-line therapies that are going to be launched in the forecasted period includes, AL3818 (anlotinib) and Fibromun. The second-line emerging therapies include Vigil in combination with irinotecan and temozolomide, AL3818, GSK 3377794, Ripretinib (DCC-2618), Tazemetostat, Abemaciclib, Pembrolizumab, Crizotinib, ABI-009, and SRA737. The third-line emerging therapies include Avapritinib, Cabozantinib, and Selinexor. The fourth-line emerging therapies include Avapritinib, TAS-116, Crenolanib, and Ripretinib.
Soft Tissue Sarcoma Market Outlook
The Soft Tissue Sarcoma market size is expected to increase at a significant CAGR during the study period (2017–2030). Among all the seven major markets, the United States accounts for the highest Soft Tissue Sarcoma market size. Among EU5, Germany had the highest Soft Tissue Sarcoma market size in 2017 USD 22.06 million, followed by Italy. The market size of STS (excluding GIST) in Japan was found to be least in 2017.
The key companies involved for Soft Tissue Sarcoma market treatment are Amgen, BioPharma, AstraZeneca and many others.
Soft Tissue Sarcoma Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the Soft Tissue Sarcoma market or expected to get launched in the market during the study period 2017-2030. The analysis covers Soft Tissue Sarcoma market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The current Soft Tissue Sarcoma market size is mainly attributed to Votrient, Yondelis, Halaven, and various anthracycline and non-anthracycline regimens. The market size of GIST in the United States was found to be USD 119.7 million in 2017 and expected to increase during the forecast period (2020–2030) due to potential therapies Vitrakvi, Rozlytrek, Avapritinib, Ripretinib and others.
Report Highlights
· In the coming years, Soft Tissue Sarcoma market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the Soft Tissue Sarcoma market size to enable the drug manufacturers to penetrate more into the market
· Major players like Blueprint Medicines Corporation, Gradalis, Karyopharm Therapeutics and many others are involved in developing therapies for Soft Tissue Sarcoma. Launch of emerging therapies will significantly impact the Soft Tissue Sarcoma market
· A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Soft Tissue Sarcoma
· Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Soft Tissue Sarcoma Report Insights
· Patient Population
· Therapeutic Approaches
· Soft Tissue Sarcoma Pipeline Analysis
· Soft Tissue Sarcoma Market Size and Trends
· Market Opportunities
· Impact of upcoming Therapies
Download a free sample report on Soft Tissue Sarcoma:
https://www.delveinsight.com/report-store/soft-tissue-sarcoma-market
#soft tissue sarcoma#Soft Tissue Sarcoma market#Soft Tissue Sarcoma market share#Soft Tissue Sarcoma market size#soft tissue sarcoma market trends#Soft Tissue Sarcoma market research reports#Soft Tissue Sarcoma market size and share
0 notes
Text
Dedifferentiated Liposarcoma Treatment Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026
Liposarcoma refers to one of the most commonly diagnosed type of soft tissue sarcomas. It is a type of cancer that originates from the fat cells in deep tissues. On the other hand, dedifferentiated Liposarcoma is the least common subtypes among all types of sarcomas and arises from a well-differentiated sarcoma. The tumors of dedifferentiated Liposarcoma are typically present in the retroperitoneal/abdominal cavity followed by the limbs. The reason for development of these tumors are still unknown, however, genetic mutations is considered to be one of the factors in generation of these tumors. The most commonly employed treatment for dedifferentiated sarcoma includes complete excision and removal of the tumor by various therapies such as liposuction and targeted immunotherapy. Dedifferentiated Liposarcoma does not have any gender predilection, however, is commonly found in patients over the age of 50 years. The global dedifferentiated Liposarcoma treatment market is expected to exhibit a moderate growth rate, which attributes to low incidence of the disease across the globe. According to the World Health Organization 2016, the incidence rate of well-differentiated Liposarcoma accounts for 2.5 per million, wherein de-differentiated Liposarcoma accounts for 18% of the total incidence of Liposarcoma across the globe.
Regional Insights
On the basis of region, the global dedifferentiated Liposarcoma treatment market by Coherent Market Insights is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America holds the dominant position in the global dedifferentiated Liposarcoma treatment market, owing to increasing research and development of novel therapies and potential drugs for dedifferentiated Liposarcoma. For instance, the Sarcoma Foundation of America (SFA) aids sarcoma patients by providing funding for research to private researchers and conducts education campaigns for patients suffering from various types of sarcomas.
Furthermore, Asia Pacific market is expected to gain significant traction in the near future, owing to increasing research and development of new drugs and immunotherapies, to combat the disease as well as presence of significant population suffering from the disease in this region. For instance, according to the Journal of Blood & Lymph 2013, in India up to 35% of patients suffering with Sarcoma died due to dedifferentiated Liposarcoma, wherein the total number of deaths as a result of sarcoma was reported to be 328 patients in 2012.
Competitive Analysis
Key players operating in the global dedifferentiated Liposarcoma treatment market include Johnson & Johnson Services, Inc., Eli Lily & Company, Novartis AG, Pfizer, Inc. and Sanofi SA. Major players are focusing on innovation and development, to maintain their position in the market and enhance its share. For instance, in July 2017, Karyopharm Therapeutics, Inc. cleared Phase II clinical trial for Selinexor, an orally administered inhibitor of CRM1, to treat patients with unresectable dedifferentiated liposarcoma.
Market Taxonomy:
The chemotherapy segment is expected to be dominant, owing to widespread availability of drugs across the world. According to the British Medical Journal, the European Medical Agency approved the use of 48 cancer drugs for 68 indications in Europe. Moreover, patent expiry is leading to entrance of large number of generic players in the market, which also propels growth of chemotherapy segment. However, immunotherapy is expected to gain marginal traction in the forecast period, owing to extensive research and development associated with the implementation of targeted cell therapy and other immunotherapies that have lower side effects than the chemotherapy. According to Memorial Sloan Kettering Cancer Center 2015, checkpoint inhibitor based immunotherapy is being effectively tested against dedifferentiated Liposarcoma and has potential benefits in treating the disorder.
Ask For Discount Before Purchasing This Business Report @
On the basis of treatment type, the global dedifferentiated Liposarcoma treatment market is segmented into:
Chemotherapy
Immunotherapy
Radiation Therapy
On the basis of end user, the global dedifferentiated Liposarcoma treatment market is segmented into:
Hospitals
Multispecialty Clinics
Cancer Treatment & Rehabilitation Centers
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]
0 notes
Text
Retroperitoneal Liposarcoma Treatment Market Share, Outlook 2026
Retroperitoneal Liposarcoma Treatment Market Share, Outlook 2026
Retroperitoneal liposarcoma (RLS) is a rare, biologically heterogeneous cancer, which occurs in retroperitoneum, lining of the abdominal space that covers the abdominal organs. Retroperitoneal liposarcoma grow continuously and may not get diagnosed until they are very large thus, its prognosis is poor compared to the other subtypes of retroperitoneal sarcomas. The reason for the development of…
View On WordPress
#Retroperitoneal Liposarcoma Treatment#Retroperitoneal Liposarcoma Treatment Market#Retroperitoneal Liposarcoma Treatment Market Size
0 notes